Published

Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Expert opinion on drug safety
Date: 2022-06-01
Source: PubMed
DOI: 10.1080/14740338.2022.2063274
PubMed: 35387542

Authors

Husain MI Umer M Mulsant BH

Watch author

Derived topics and classifications

psilocybin Depression PTSD Addiction Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility.Frontiers in neuroscience · 2026-01-01 Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimizationFrontiers in Psychiatry · 2025-04-08 Psychedelics in psychiatric treatment: a literature reviewQuality in Sport · 2026-01-26 Should addiction researchers be interested in psychedelic science?Drug and Alcohol Review · 2017-04-10 Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.CNS drugs · 2024-10-01 The need for publicly funded research on therapeutic use of psychedelic drugsWorld Psychiatry · 2021-05-18 Gregor Hasler: Three Guiding Questions - How do psychedelics shape the brain? How can they heal psychiatric disorders such as depression and PTSD? How can we ensure their safe and responsible use?Psychedelics. · 2025-09-02 Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.International review of psychiatry (Abingdon, England) · 2024-12-01